Article
Oncology
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Summary: This study investigated the effectiveness and safety of combining sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). The results showed that the combination therapy significantly improved tumor response rates, overall survival, and time to progression compared to sorafenib monotherapy. However, the DTS group had a higher incidence of adverse events during treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Surgery
Hiroji Shinkawa, Shogo Tanaka, Shigekazu Takemura, Ryosuke Amano, Kenjiro Kimura, Masahiko Kinoshita, Kanae Takahashi, Shuichiro Matsuzaki, Shoji Kubo
Summary: The study developed two reliable nomograms to predict extrahepatic recurrence and early intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. These nomograms showed good predictive performance and could guide the selection of treatment strategies for hepatocellular carcinoma patients by surgeons.
Article
Medicine, Research & Experimental
Shuhua Wei, Fenghua Wei, Mengyuan Li, Yuhan Yang, Jingwen Zhang, Chunxiao Li, Junjie Wang
Summary: Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment, especially hepatocellular carcinoma (HCC). However, many cancer patients acquire drug resistance to sorafenib in subsequent treatment, and the immunological mechanisms behind this resistance are still unclear. This review focuses on the immunoregulatory effects of sorafenib on the tumor microenvironment, the potential immunological mechanisms of therapeutic resistance, and the combination of sorafenib with immunotherapy to improve efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Pathology
Deepika Kumar, Omeed Hafez, Dhanpat Jain, Xuchen Zhang
Summary: This study compared the histomorphologic features and phenotypic heterogeneity between primary and metastatic hepatocellular carcinoma (HCC) using 39 cases with both primary and metastatic tissues. The findings revealed significant intratumoral heterogeneity and histomorphologic discordance between primary and metastatic HCCs, with certain histologic patterns and subtypes being closely associated with metastasis. Further studies on a larger cohort are needed to better understand the mechanisms of HCC metastasis.
Review
Pharmacology & Pharmacy
Xinchen Tian, Tinghao Yan, Fen Liu, Qingbin Liu, Jing Zhao, Huabao Xiong, Shulong Jiang
Summary: The "Translation" section introduces the limitations of sorafenib treatment for hepatocellular carcinoma, including drug resistance. It mentions the important roles of tumor microenvironment and immune escape in tumor occurrence and resistance to anti-cancer drugs, highlighting the importance of overcoming sorafenib resistance in liver cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Yutaka Kurebayashi, Naoto Kubota, Michiie Sakamoto
Summary: The tumor microenvironment, consisting of tumor cells, immune cells, and non-immune stromal cells, plays a crucial role in regulating tumor growth. Different patterns of immune microenvironment are observed among different tumor subtypes, with intense studies on their clinicopathological significance and intertumor/intratumor heterogeneity.Understanding the comprehensive histopathological picture of a tumor immune microenvironment is essential for precision medicine in the era of tumor-targeting immunotherapy.
HEPATOLOGY RESEARCH
(2021)
Article
Oncology
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Summary: This study found that serum IgA levels are associated with the infiltration of inflammatory IgA(+)PD-L1(high) monocytes in the liver and tumor microenvironment in chronic liver diseases and hepatocellular carcinoma (HCC). These findings provide potential therapeutic targets.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Letter
Oncology
Heewon Bae, Je Ryung Gil, Moon Hyung Lee, Taekyu Lim
Summary: A patient with hepatocellular carcinoma(HCC) received chemotherapy for intrahepatic recurrence after hepatic segmentectomy. Regorafenib was used as a second-line treatment, but discontinued due to side effects. Unexpected long-term regression was observed after two years of follow-up, suggesting the potential of regorafenib for anti-tumor immunity through pharmacological mechanisms.
Review
Medicine, General & Internal
Hai-Yi Long, Tong-Yi Huang, Xiao-Yan Xie, Jian-Ting Long, Bao-Xian Liu
Summary: This review highlights the significance of extrahepatic metastasis in the treatment of hepatocellular carcinoma, emphasizing the roles of systemic agents and locoregional management while discussing the potential of immunotherapy in HCC treatment.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Surgery
Shigeki Nakagawa, Yo-Ichi Yamashita, Naoki Umezaki, Takanobu Yamao, Takayoshi Kaida, Yukiharu Hiyoshi, Kosuke Mima, Hirohisa Okabe, Hiromitsu Hayashi, Katsunori Imai, Akira Chikamoto, Hideo Baba
Summary: The study aimed to identify the gene signature for intrahepatic metastasis to predict hepatocellular carcinoma recurrence. The high-risk prediction was found to be associated with higher early hepatocellular carcinoma recurrence, and gene sets related to cell cycle and histone modulation were enriched in the high intrahepatic metastasis gene signature group.
Article
Medicine, Research & Experimental
Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
Summary: This study demonstrated that the combination of fucoidan and sorafenib could overcome sorafenib resistance in hepatocellular carcinoma cells by interacting with cell membrane EGFR and suppressing EGFR redistribution and downstream signaling. The simultaneous treatment of fucoidan and sorafenib might serve as a potential therapeutic strategy against sorafenib-resistant HCC.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Summary: Clinical studies have shown that immunotherapy is more effective than sorafenib for advanced hepatocellular carcinoma, but the outcomes of HAIC with cisplatin compared to sorafenib remain unclear. This study found that HAIC with cisplatin significantly prolonged overall survival for intrahepatic advanced HCC, particularly for patients in Child-Pugh class A.
Article
Multidisciplinary Sciences
Ji Won Han, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Summary: Elevated diastolic whole blood viscosity (WBV) is associated with distant metastases and poor survival in patients with hepatocellular carcinoma (HCC). High diastolic WBV is an independent risk factor for poor survival and may be predictive of future distant metastases.
Article
Oncology
Feng Qi, Wenxing Qin, Yao Zhang, Yongde Luo, Bing Niu, Quanlin An, Biwei Yang, Keqing Shi, Zhijie Yu, Junwei Chen, Xin Cao, Jinglin Xia
Summary: The study identified sulfarotene as a selective inhibitor for TRCs in HCC, targeting a novel RAR alpha-SOS2-RAS signaling pathway, providing a promising strategy for targeted therapy in advanced liver cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Won Ick Chang, Byoung Hyuck Kim, Yoon Jun Kim, Jung-Hwan Yoon, Yong Jin Jung, Eui Kyu Chie
Summary: This study aimed to investigate the clinical benefits of locoregional radiation therapy (RT) before, after, and concurrent with sorafenib therapy for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients. The results showed that locoregional RT was associated with significantly longer survival in BCLC stage C HCC patients who were treated with sorafenib, especially in patients treated with sorafenib for 12 weeks or more. Incorporating locoregional RT could improve the dismal prognosis for these patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Surgery
Naruhiko Honmyo, Tsuyoshi Kobayashi, Shintaro Kuroda, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Hiroshi Morimoto, Naoki Tanimine, Michinori Hamaoka, Megumi Yamaguchi, Masateru Yamamoto, Daisuke Takei, Hiroshi Aikata, Kazuaki Chayama, Hideki Ohdan
Summary: This study identified risk factors for hepatocellular carcinoma (HCC) development after splenectomy for portal hypertension. The etiology of cirrhosis, presence of HCC history, and preoperative hemoglobin level were found to be associated with HCC development. The predictive model constructed in this study may assist in surveillance for HCC after splenectomy in patients with portal hypertension.
Article
Virology
Toshitada Takemori, Akiko Sugimoto-Ishige, Hironori Nishitsuji, Yushi Futamura, Michishige Harada, Tomomi Kimura-Someya, Takehisa Matsumoto, Teruki Honma, Miho Tanaka, Masami Yaguchi, Kyoichi Isono, Haruhiko Koseki, Hiroyuki Osada, Daiki Miki, Takashi Saito, Takashi Tanaka, Takehiro Fukami, Toshio Goto, Mikako Shirouzu, Kunitada Shimotohno, Kazuaki Chayama
Summary: Entry inhibitors are being developed to enhance the treatment of HBV patients with oral nucleoside/nucleotide analogues (NA). Therapeutic MAbs with neutralizing activity against HBs antigens have been developed to amplify the effectiveness of NA therapy. Targeting NTCP can provide an effective treatment option for patients with chronic hepatitis B, regardless of viral genotype, mutations, and the presence of subviral particles.
JOURNAL OF VIROLOGY
(2022)
Review
Gastroenterology & Hepatology
C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama
Summary: Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment.
LIVER INTERNATIONAL
(2022)
Article
Multidisciplinary Sciences
Kenji Yamaoka, Kenichiro Kodama, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Shigeki Yano, Serami Murakami, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Michio Imamura, Shoichi Takahashi, Akiko Nagao, Kazuaki Chayama, Hiroshi Aikata
Summary: The study found that assessing body composition before and after lenvatinib treatment using BIA can be useful in predicting prognosis in patients with hepatocellular carcinoma.
Article
Endocrinology & Metabolism
Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yukiko Nakano, Masato Kajikawa, Kenichi Yoshimura, Gaku Aoki, Kazuaki Chayama, Chikara Goto, Aya Mizobuchi, Yiming Han, Farina Mohamad Yusoff, Shinji Kishimoto, Tatsuya Maruhashi, Ayumu Nakashima, Yukihito Higashi
Summary: This study investigated the relationship between HbA1c levels and vascular function in patients with type 2 diabetes mellitus receiving antidiabetic drug treatment. Results showed an inverted U-shaped association between HbA1c levels and FMD, with both low (<6.5%) and high (>= 8.0%) HbA1c levels associated with endothelial dysfunction, while vascular smooth muscle function was similar regardless of HbA1c levels.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Shinsuke Uchikawa, Tomokazu Kawaoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Daiki Miki, Michio Imamura, Hiroshi Aikata
Summary: This study assessed the impact of obesity on the evaluation of liver fibrosis and steatosis using 2D shear wave elastography and attenuation imaging. The results showed that 2D shear wave elastography had comparable ability to stratify fibrosis stage and steatosis grade as traditional elastography. The measurement rate was also high regardless of obesity. Furthermore, the use of an XL probe improved diagnostic accuracy for severe fibrosis in obese patients.
JOURNAL OF MEDICAL ULTRASONICS
(2022)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Jeong Heo, Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Qing Xie, Jidong Jia, Yoshiyasu Karino, Jinlin Hou, Kazuaki Chayama, Michio Imamura, Judy Y. Lao-Tan, Seng Gee Lim, Yasuhito Tanaka, Wen Xie, Jung-Hwan Yoon, Zhongping Duan, Masayuki Kurosaki, Sung-Jae Park, Madalinee Eternity Labio, Rajneesh Kumar, Young-Oh Kweon, Hyung Joon Yim, Yu Tao, Jennifer Cremer, Robert Elston, Matt Davies, Sharon Baptiste-Brown, Kelong Han, Fiona M. Campbell, Melanie Paff, Dickens Theodore
Summary: This study evaluated the safety and efficacy of GSK3389404, a drug targeting chronic HBV infection. The results showed that GSK3389404 can reduce the production of HBV viral proteins, although no optimal dosing regimen was identified.
JOURNAL OF HEPATOLOGY
(2022)
Article
Genetics & Heredity
Hiroki Kiyose, Hidewaki Nakagawa, Atsushi Ono, Hiroshi Aikata, Masaki Ueno, Shinya Hayami, Hiroki Yamaue, Kazuaki Chayama, Mihoko Shimada, Jing Hao Wong, Akihiro Fujimoto
Summary: This study utilized the Oxford Nanopore sequencer to analyze cDNA sequences from hepatocellular carcinoma and matched non-cancerous livers, revealing numerous novel transcripts and thousands of differentially expressed transcripts. Experimental results demonstrated that differentially expressed transcripts can promote cell growth, and fusion gene detection uncovered novel fusion events.
Article
Radiology, Nuclear Medicine & Medical Imaging
Shinsuke Uchikawa, Tomokazu Kawaoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Daiki Miki, Michio Imamura, Hiroshi Aikata
Summary: This study aimed to identify CEUS parameters for predicting the efficacy of atezolizumab plus bevacizumab combination therapy in hepatocellular carcinoma (HCC) patients. The results showed that CEUS at 5 weeks after initiation of Atezo + Bev may predict progression-free survival (PFS) in HCC patients. Post area under the curve (post AUC) was identified as a predictive factor for early progressive disease (PD).
JOURNAL OF MEDICAL ULTRASONICS
(2023)
Article
Gastroenterology & Hepatology
Yuki Shirane, Eisuke Murakami, Michio Imamura, Masanari Kosaka, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Daiki Miki, Masami Yamauchi, Wataru Okamoto, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Hiroshi Aikata, Shiro Oka
Summary: This study aimed to investigate the clinical significance of HVPG, subsequent EVs exacerbation, and prognosis in patients with GV treated with BRTO. It was found that HVPG increases after BRTO, and post-HVPG has a higher predictive ability for EVs exacerbation than pre-HVPG. In addition, liver stiffness measurement is a potential prognostic parameter in patients who undergo BRTO.
BMC GASTROENTEROLOGY
(2022)
Article
Oncology
Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Hiroshi Aikata
Summary: This study aimed to identify the risk factors for early onset of proteinuria in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. The study found that controlling blood pressure is extremely important for the management of proteinuria in these patients.
Article
Oncology
Yosuke Tamura, Atsushi Ono, Hikaru Nakahara, Clair Nelson Hayes, Yasutoshi Fujii, Peiyi Zhang, Masami Yamauchi, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Masahiro Serikawa, Daiki Miki, Tomokazu Kawaoka, Wataru Okamoto, Michio Imamura, Yuko Nakamura, Kazuo Awai, Tsuyoshi Kobayashi, Hideki Ohdan, Masashi Fujita, Hidewaki Nakagawa, Kazuaki Chayama, Hiroshi Aikata, Shiro Oka
Summary: High-intensity Gd-EOB-DTPA-enhanced MRI imaging (EOB-MRI) in the hepatobiliary phase (HB) can predict the immune microenvironment and molecular subtype in hepatocellular carcinoma (HCC) patients but not the response to atezolizumab + bevacizumab therapy. The high-intensity group benefits from bevacizumab, while the low-intensity group benefits from atezolizumab.
Article
Gastroenterology & Hepatology
Ryoichi Miura, Tomokazu Kawaoka, Michio Imamura, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Takao Hinoi, Hiroshi Aikata
Summary: BRIC is a genetically heterogeneous liver disorder characterized by recurrent episodes of jaundice and pruritus. This study identified novel nonsense mutations in the ATP8B1 gene as the cause of BRIC1.
CASE REPORTS IN GASTROENTEROLOGY
(2022)
Meeting Abstract
Oncology
Daiki Miki, Hiroshi Aikata, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Kazuaki Chayama
